Rhythm's Imcivree Fails Phase 3 for Rare Genetic Obesity
The MC4R agonist missed its endpoint, but the bigger question is an FDA ruling on hypothalamic obesity due this week.
Rhythm Pharmaceuticals' Imcivree failed a Phase 3 trial for rare genetic forms of obesity, according to a news briefing from Endpoints News.
The MC4R agonist missed its primary endpoint in the EMANATE trial, which tested the drug across four rare, genetically driven obesities linked to the melanocortin-4 receptor pathway,Endpoints reported.
The setback comes as Rhythm awaits an FDA decision on a much larger indication: hypothalamic obesity, which analysts have valued at over $2 billion in peak sales. The regulatory verdict is due this week.
Imcivree is already approved for two rare genetic obesity conditions and made $194.8 million in 2025. But the hypothalamic obesity decision is the binary event that will determine whether this Phase 3 miss matters much at all.